Prognostic impact of neoadjuvant chemotherapy induced neutropenia on operable breast cancer
10.3760/cma.j.issn.1007-631X.2011.08.010
- VernacularTitle:新辅助化疗诱导的粒细胞减少症对乳腺癌预后的影响
- Author:
Yunwei HAN
;
Xin WANG
;
Bin ZHANG
;
Shaoyan WEN
;
Wei LIU
;
Xuchen CAO
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Neutropenia;
Antineoplastic combined chemotherapy protocol;
Prognosis
- From:
Chinese Journal of General Surgery
2011;26(8):651-654
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the relationship between neoadjuvant chemotherapy (combination of taxanes and anthracyclines ) induced-neutropenia and the efficacy of neoadjuvant chemotherapy and long-term survival in operable breast cancer patients. Methods Two hundred and eleven patients received 4 cycles of neoadjuvant chemotherapy (combination of taxanes and anthracyclines).Clinicopathological characteristics were compared between patients with neoadjuvant chemotherapy-induced neutropenia and patients without neutropenia. The efficacy of neoadjuvant chemotheray and long-term survival rate were analyzed. Results Among 211 patients there were 51 (24. 2% ) cases suffering from neutropenia and 160 (75.8%) cases were of no-neutropenia. The response to chemotherapy in patients with neutropenia were more effective than in no- neutropenia ones ( P ＜ 0. 05 ). The 5-year disease-free survival (DFS) in patients with neutropenia was 82. 4%, while the 5-year disease-free survival ( DFS) with nonneutropenia was 60% ( P ＜ 0. 01 ). Additionally, the 5-year overall survival ( OS ) in patients with neutropenia was 90. 2% and in patients with non-neutropenia patients was 67. 5% ( P ＜ 0. 01 ).Conclusions Chemotherapy-induced neutropenia during neoadjuvant chemotherapy combination of taxanes and anthracyclines in patients with operable breast cancer has a better prognosis. The sensitivity of tumors given to chemotherapeutic drugs could be evaluated by chemotherapy-induced neutropenia.
